Advanced Enzyme Technologies (ADVENZYMES) Q4 25/26 earnings summary

Executive summary

• Achieved record quarterly and annual revenue for FY 2026, with strong growth across all business divisions and segments, despite global supply chain disruptions and inflationary pressures.

• Approved audited standalone and consolidated financial results for the year ended March 31, 2026, and the fourth quarter results.

• Maintained consistent supply and operational performance, supported by strategic investments in R&D and expansion into new geographies.

• Focused on innovation, regulatory filings, and operational efficiency to drive future growth.

• Board approved re-appointment of Mr. Mukund Kabra as Whole Time Director and appointment of Mr. Pradip Shah as Independent Director, both subject to AGM approval.

Financial highlights

• Q4 FY26 revenue: ₹2,034 million (+22% y-o-y, +18% q-o-q); EBITDA: ₹632 million (+39% y-o-y, +28% q-o-q); PAT: ₹453 million (+69% y-o-y, +5% q-o-q).

• FY26 revenue: ₹7,458 million (+17% y-o-y); EBITDA: ₹2,291 million (+18% y-o-y); PAT: ₹1,736 million (+30% y-o-y); EPS: ₹15.08, up 29% year-over-year.

• Consolidated net profit for FY 2025-26 was ₹2,684.19 million, compared to ₹1,527.96 million in the previous year.

• Subsidiaries JC Biotech, Evoxx, and SciTech all reported significant revenue and profitability improvements.

• Net worth at FY26: ₹16,320 million.

Outlook and guidance

• Expecting steady momentum and double-digit growth in FY 2027, with continued focus on capacity optimization, supply chain efficiency, and new product launches.

• Margins anticipated to remain stable, with possible 1-2% variability due to inflation and cost pressures, especially in the U.S.

• Focus on expanding product portfolio in animal nutrition, probiotics, and bio-catalysis, and broadening geographical presence, especially in USA, MENA, and Asia.

• Continued investment in R&D and inorganic expansion to drive future growth.

• Final dividend of ₹1.35 per share proposed, with payment after AGM approval.